Logo image of BPTH

BIO-PATH HOLDINGS INC (BPTH) Stock Fundamental Analysis

USA - NASDAQ:BPTH - US09057N4097 - Common Stock

0.21 USD
-0.42 (-66.84%)
Last: 2/18/2025, 8:00:01 PM
0.2142 USD
+0 (+2%)
After Hours: 2/18/2025, 8:00:01 PM
Fundamental Rating

0

Overall BPTH gets a fundamental rating of 0 out of 10. We evaluated BPTH against 534 industry peers in the Biotechnology industry. BPTH has a bad profitability rating. Also its financial health evaluation is rather negative. BPTH does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BPTH has reported negative net income.
In the past year BPTH has reported a negative cash flow from operations.
In the past 5 years BPTH always reported negative net income.
BPTH had a negative operating cash flow in each of the past 5 years.
BPTH Yearly Net Income VS EBIT VS OCF VS FCFBPTH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5M -10M -15M

1.2 Ratios

BPTH has a Return On Assets of -354.57%. This is amonst the worse of the industry: BPTH underperforms 96.26% of its industry peers.
Industry RankSector Rank
ROA -354.57%
ROE N/A
ROIC N/A
ROA(3y)-208.48%
ROA(5y)-145.89%
ROE(3y)-1261.55%
ROE(5y)-779.53%
ROIC(3y)N/A
ROIC(5y)N/A
BPTH Yearly ROA, ROE, ROICBPTH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -1K -2K -3K

1.3 Margins

BPTH does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BPTH Yearly Profit, Operating, Gross MarginsBPTH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20K -40K -60K

More info and screens

0

2. Health

2.1 Basic Checks

BPTH has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, BPTH has more shares outstanding
BPTH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BPTH Yearly Shares OutstandingBPTH Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 200K 400K 600K
BPTH Yearly Total Debt VS Total AssetsBPTH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M

2.2 Solvency

BPTH has an Altman-Z score of -68.03. This is a bad value and indicates that BPTH is not financially healthy and even has some risk of bankruptcy.
BPTH has a worse Altman-Z score (-68.03) than 95.54% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -68.03
ROIC/WACCN/A
WACCN/A
BPTH Yearly LT Debt VS Equity VS FCFBPTH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M

2.3 Liquidity

A Current Ratio of 0.86 indicates that BPTH may have some problems paying its short term obligations.
BPTH has a Current ratio of 0.86. This is amonst the worse of the industry: BPTH underperforms 90.37% of its industry peers.
A Quick Ratio of 0.86 indicates that BPTH may have some problems paying its short term obligations.
BPTH has a Quick ratio of 0.86. This is amonst the worse of the industry: BPTH underperforms 89.48% of its industry peers.
Industry RankSector Rank
Current Ratio 0.86
Quick Ratio 0.86
BPTH Yearly Current Assets VS Current LiabilitesBPTH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M

More info and screens

1

3. Growth

3.1 Past

BPTH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 66.03%, which is quite impressive.
EPS 1Y (TTM)66.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.06%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

BPTH is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.40% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y91.32%
EPS Next 2Y39.91%
EPS Next 3Y25.14%
EPS Next 5Y15.4%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BPTH Yearly Revenue VS EstimatesBPTH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2028 2029 2030 2031 20M 40M 60M 80M 100M
BPTH Yearly EPS VS EstimatesBPTH Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -100 -200 -300

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

BPTH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BPTH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BPTH Price Earnings VS Forward Price EarningsBPTH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BPTH Per share dataBPTH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -2 -4 -6 -8 -10

4.3 Compensation for Growth

A more expensive valuation may be justified as BPTH's earnings are expected to grow with 25.14% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.91%
EPS Next 3Y25.14%

More info and screens

0

5. Dividend

5.1 Amount

BPTH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIO-PATH HOLDINGS INC

NASDAQ:BPTH (2/18/2025, 8:00:01 PM)

After market: 0.2142 +0 (+2%)

0.21

-0.42 (-66.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2024-11-14/amc
Earnings (Next)03-07 2025-03-07/amc
Inst Owners7.41%
Inst Owner Change0%
Ins Owners0.04%
Ins Owner Change0%
Market Cap905.10K
Revenue(TTM)N/A
Net Income(TTM)-10513000
Analysts82.86
Price Target12.24 (5728.57%)
Short Float %0.16%
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)29.44%
Min EPS beat(2)26.15%
Max EPS beat(2)32.72%
EPS beat(4)2
Avg EPS beat(4)6.37%
Min EPS beat(4)-28%
Max EPS beat(4)32.72%
EPS beat(8)4
Avg EPS beat(8)-2.97%
EPS beat(12)5
Avg EPS beat(12)-7.88%
EPS beat(16)9
Avg EPS beat(16)-0.13%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)48.87%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-13.79
EYN/A
EPS(NY)-1.58
Fwd EYN/A
FCF(TTM)-2.21
FCFYN/A
OCF(TTM)-2.21
OCFYN/A
SpS0
BVpS-0.17
TBVpS-0.17
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -354.57%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-208.48%
ROA(5y)-145.89%
ROE(3y)-1261.55%
ROE(5y)-779.53%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.86
Quick Ratio 0.86
Altman-Z -68.03
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)66.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.06%
EPS Next Y91.32%
EPS Next 2Y39.91%
EPS Next 3Y25.14%
EPS Next 5Y15.4%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y26.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y26.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y26.32%
OCF growth 3YN/A
OCF growth 5YN/A

BIO-PATH HOLDINGS INC / BPTH FAQ

Can you provide the ChartMill fundamental rating for BIO-PATH HOLDINGS INC?

ChartMill assigns a fundamental rating of 0 / 10 to BPTH.


Can you provide the valuation status for BIO-PATH HOLDINGS INC?

ChartMill assigns a valuation rating of 1 / 10 to BIO-PATH HOLDINGS INC (BPTH). This can be considered as Overvalued.


What is the profitability of BPTH stock?

BIO-PATH HOLDINGS INC (BPTH) has a profitability rating of 0 / 10.


What is the expected EPS growth for BIO-PATH HOLDINGS INC (BPTH) stock?

The Earnings per Share (EPS) of BIO-PATH HOLDINGS INC (BPTH) is expected to grow by 91.32% in the next year.